XML 146 R110.htm IDEA: XBRL DOCUMENT v3.21.2
Related Party Transactions (Details) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2020
Dec. 31, 2019
Related Party Transaction [Line Items]            
Accounts payable due to related parties $ 44,201   $ 44,201   $ 149,067 $ 92,744
CEO            
Related Party Transaction [Line Items]            
Compensation amount received related to related party transaction 137,500 $ 53,125 286,250 $ 121,875 456,459 452,400
Neuro Rx | Chief Executive Officer Son [Member]            
Related Party Transaction [Line Items]            
Payment to related party 4,615 4,820 6,110 4,820    
Neuro Rx | Chief Executive Officer and Chairman of Board            
Related Party Transaction [Line Items]            
Payment to related party 254,936 0 395,757 0 271,082  
Neuro Rx | Chief Commercial Officer            
Related Party Transaction [Line Items]            
Payment to related party 11,100 18,605 29,740 40,770 85,915 48,000
Neuro Rx | CEO            
Related Party Transaction [Line Items]            
Payment to related party         11,650  
Neuro Rx | Glytech Agreement            
Related Party Transaction [Line Items]            
Continuing technology support services and reimbursed expenses $ 125,000 $ 0 $ 125,000 $ 82,569 $ 272,929 $ 464,720
Related party transaction description     The Excluded Technology will transfer to the Company for no additional consideration if the value of NRx Pharmaceuticals equity held by Glytech exceeds $50,000,000 at any time prior to August 6, 2022. After August 6, 2022, the additional IP will transfer to the Company at no cost.   The Excluded Technology will transfer to the Company for no additional consideration if the value of NeuroRx equity held by Glytech exceeds $50,000,000 at any time prior to August 6, 2022. After August 6, 2022, the additional IP will transfer to the Company at no cost.